Kornelia Polyak

Last updated
Kornelia Polyak
Alma mater
Scientific career
Institutions

Kornelia Polyak is a professor of medicine at Harvard Medical School and an internationally recognized breast cancer expert. [1]

Polyak earned her MD from Albert Szent-Gyorgyi Medical University in Szeged, Hungary, and her PhD from Weill Cornell Graduate School of Medical Sciences/Sloan-Kettering Cancer Center in New York City. She then did a fellowship in cancer genetics at Johns Hopkins Oncology Center with Bert Vogelstein and Kenneth Kinzler. [2]

In 1998, Polyak joined the faculty of Dana–Farber Cancer Institute. [2] Her research focuses on breast tumor evolution. [3] Her research is funded in part by the Breast Cancer Research Foundation. [4]

From 2010 to 2013, she served on the American Association for Cancer Research Board of Directors, [2] and from 2015 to 2019, she was a member of the AACR Women in Cancer Research council. [2]

Awards

Related Research Articles

<span class="mw-page-title-main">Weill Cornell Medicine</span> Medical school of Cornell University

The Joan & Sanford I. Weill Medical College of Cornell University is Cornell University's biomedical research unit and medical school in New York City. It is affiliated with NewYork-Presbyterian Hospital, Weill Cornell Medical Center, Hospital for Special Surgery, Memorial Sloan Kettering Cancer Center, and Rockefeller University, all of which are located on or near York Avenue and Sutton Place.

<span class="mw-page-title-main">José Baselga</span> Spanish oncologist (1959–2021)

Josep Baselga i Torres, known in Spanish as José Baselga, was a Spanish medical oncologist and researcher focused on the development of novel molecular targeted agents, with a special emphasis in breast cancer. Through his career he was associated with the Memorial Sloan Kettering Cancer Center, Vall d'Hebron Institute of Oncology, and the Massachusetts General Hospital in their hematology and oncology divisions. He led the development of the breast cancer treatment Herceptin, a monoclonal antibody, that targets the HER2 protein, which is impacted in aggressive breast cancers.

<span class="mw-page-title-main">Victor Velculescu</span>

Victor E. Velculescu is a Professor of Oncology and Co-Director of Cancer Biology at Johns Hopkins University School of Medicine. He is internationally known for his discoveries in genomics and cancer research.

<span class="mw-page-title-main">Joseph F. Fraumeni Jr.</span> American physician and cancer researcher

Joseph F. Fraumeni Jr. is an American physician and cancer researcher. Born in Boston, he received an A.B. from Harvard College, an M.D. from Duke University, and an M.Sc. in epidemiology from the Harvard School of Public Health. He completed his medical residency at Johns Hopkins Hospital and Memorial Sloan Kettering Cancer Center. He then joined the National Cancer Institute at the National Institutes of Health in 1962 as a commissioned officer of the U.S. Public Health Service, becoming the founding Director of the Division of Cancer Epidemiology and Genetics in 1995. He stepped down from this position in 2012 to become a senior investigator and advisor to the National Cancer Institute.

<span class="mw-page-title-main">Olufunmilayo Olopade</span> Nigerian physician

Olufunmilayo I. Olopade born in the year 1957, is a Nigerian hematology oncologist, Associate Dean for Global Health and Walter L. Palmer, Distinguished Service Professor in Medicine and Human Genetics at the University of Chicago. She also serves as director of the University of Chicago Hospital's Cancer Risk Clinic.

Laurie Hollis Glimcher is an American physician-scientist who was appointed president and CEO of Dana–Farber Cancer Institute in October 2016. She was elected a Member of the American Philosophical Society in 2019.

<span class="mw-page-title-main">Kenneth Offit</span> American geneticist

Kenneth Offit is an American cancer geneticist and oncologist. He is currently Chief of the Clinical Genetics Service and the Robert and Kate Niehaus Chair in Inherited Cancer Genomics at Memorial Sloan Kettering Cancer Center. Offit is also a member of the Program in Cancer Biology and Genetics at the Sloan-Kettering Institute, Professor of Medicine and Healthcare Policy and Research at Weill Cornell Medical College, and a member of both the Board of Scientific Counselors of the National Cancer Institute and the Evaluation of Genomic Applications in Practice and Prevention working group of the U.S. Centers for Disease Control.

<span class="mw-page-title-main">William Kaelin Jr.</span> American Nobel Laureate, Professor of Medicine at Harvard University

William G. Kaelin Jr. is an American Nobel laureate physician-scientist. He is a professor of medicine at Harvard University and the Dana–Farber Cancer Institute. His laboratory studies tumor suppressor proteins. In 2016, Kaelin received the Albert Lasker Award for Basic Medical Research and the AACR Princess Takamatsu Award. He also won the Nobel Prize in Physiology or Medicine in 2019 along with Peter J. Ratcliffe and Gregg L. Semenza.

David M. Livingston was the Deputy Director of the Dana-Farber/Harvard Cancer Center, Emil Frei Professor of Genetics and Medicine at Harvard Medical School, Chairman of the Executive Committee for Research at Dana–Farber Cancer Institute. Dr. Livingston joined the Harvard faculty in 1973. His research focused on breast and ovarian cancer.

Nancy E. Davidson is the executive director and president of Seattle Cancer Care Alliance, senior vice president, director of clinical oncology at Fred Hutchinson Cancer Research Center and head of the Division of Medical Oncology at the University of Washington School of Medicine. She focuses her research on breast cancer treatments and the genes that are mutated in various forms of breast cancer. She was president of American Association for Cancer Research from 2015 to 2016 and president of American Society of Clinical Oncology from 2007 to 2008.

Utthara Nayar is a cancer researcher based in Boston, Massachusetts. Her work focuses specifically on breast cancer.

Judy Ellen Garber is the director of the Center for Cancer Genetics and Prevention at the Dana–Farber Cancer Institute and a professor of medicine at Harvard Medical School. Garber previously served as president of the American Association for Cancer Research.

Agata Smogorzewska is a Polish-born scientist. She is an associate professor at Rockefeller University, heading the Laboratory of Genome Maintenance. Her work primarily focuses on DNA interstrand crosslink repair and the diseases resulting from deficiencies in this repair pathway, including Fanconi anemia and karyomegalic interstitial nephritis.

<span class="mw-page-title-main">Sallie Permar</span> American pediatrician

Sallie Robey Permar is the pediatrician-in-chief at NewYork-Presbyterian / Weill Cornell Medical Center and the chair of the Department of Pediatrics at Weill Cornell Medicine. Her research focuses on infections affecting newborns.

Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.

James R. Downing is an American clinical executive. He is the president and chief executive officer of St. Jude Children's Research Hospital.

Levi A. Garraway is an American oncologist. His research team was among the first to adapt genomics technologies to enable scalable, high-throughput clinical approaches to cancer gene mutation profiling. As a result, he was inducted into the American Society for Clinical Investigation, American Association for Cancer Research, and National Academy of Medicine.

Franziska Michor is an Austrian-American computational biologist who is a Professor in the Department of Data Science at the Dana–Farber Cancer Institute. She serves as Director of the Physical Sciences-Oncology Center and the Center for Cancer Evolution.

<span class="mw-page-title-main">Chi Van Dang</span> Hematological oncologist

Chi Van Dang is a hematological oncologist and researcher, currently serving as the Scientific Director of Ludwig Institute for Cancer Research. He is known for his research on genetics, the MYC gene and the cellular energy metabolism of cancer.

W. Kimryn Rathmell is an American physician-scientist whose work focuses on the research and treatment of patients with kidney cancers. She is the Hugh Jackson Morgan Professor and Chair of the Department of Medicine at Vanderbilt University Medical Center (VUMC), and Physician-in-Chief for Vanderbilt University Adult Hospital and Clinics in Nashville, Tennessee.

References

  1. "Kornelia Polyak, MD, PhD - DF/HCC". www.dfhcc.harvard.edu. Retrieved 12 April 2019.
  2. 1 2 3 4 "Kornelia Polyak, MD, PhD". www.aacr.org. Retrieved 12 April 2019.
  3. "Genetics of Breast Cancer". ndriresource.org. Retrieved 12 April 2019.
  4. "Kornelia Polyak | Researcher". Breast Cancer Research Foundation. 23 June 2014. Retrieved 12 April 2019.
  5. "The American Society for Clinical Investigation" . Retrieved 12 April 2019.